期刊文献+

十全大补汤加减治疗奥沙利铂致神经毒性22例疗效观察 被引量:4

Observation on Clinical Efficacy of Modified ShiQuan DaBuTang in Treating 22 Cases of Neurotoxicity Induced by Oxaliplatin
暂未订购
导出
摘要 目的:观察十全大补汤加减治疗奥沙利铂致神经毒性临床疗效。方法:将42例患者随机分为治疗组22例,对照组20例,2组患者均采用奥沙利铂联合化疗方案。治疗组在对照组化疗基础上加用十全大补方,水煎服,1剂/d,于用奥沙利铂前2天开始口服,12天为1个周期,连服2周期。化疗结束后继续观察随访6个月。结果:治疗组痊愈7例,占31.82%;有效12例,占54.55%;无效3例,占13.64%;总有效率86.36%。对照组痊愈3例,占15.00%;有效10例,占50.00%;无效7例,占35.00%;总有效率65.00%。2组总有效率比较有显著性差异(P<0.05),治疗组疗效优于对照组。结论:十全大补汤加减治疗奥沙利铂致神经毒性疗效显著。 Objective: To observe clinical efficacy of modified ShiQuan DaBuTang in treating neurotoxicity induced by oxaliplatin. Method: All 42 patients were randomly divided into 22 cases in treatment group and 20 cases in control group, both groups received oxaliplatin and chemotherapy. Treatment group were also administered with modified ShiQuan DaBuTang, one dose per day, begimiing to take two days before taking oxaliplatin, one session was twelve days, for two consecutive sessions. Six-month follow-ups were performed by the end of chemotherapy. Result: Seven cases were cured in treatment group and reached 31.82%; 12 cases were effective and accounted for 54.55%; three cases ineffective and 13.64%; total effective rate was 86.36%. Three cases were cured in control group and reached 15.00%; ten cases effective and 50.00%; seven cases ineffective and 35.00%; total effective rate was 65.00%. Comparisons of both groups indicated remarkable difference in total effective rate (P〈0.05), and treatment group was superior to control group in curative effects. Conclusion: Modified ShiQuan DaBuTang is effective in treating neurotoxicity.
出处 《西部中医药》 2012年第9期35-36,共2页 Western Journal of Traditional Chinese Medicine
关键词 神经毒性 奥沙利铂 十全大补汤 neurotoxicity oxaliplatin ShiQuan DaBuTang
  • 相关文献

参考文献10

  • 1汤钊猷.现代肿瘤学[M]上海:上海医科大学出版社,199685.
  • 2王莉,王琳,秦叔逵.奥沙利铂神经毒性处理及预防研究进展[J].医学综述,2006,12(8):490-492. 被引量:12
  • 3Woynarowski JM,Faivres S,Herzig MC. Oxalipla-tininduced damage of cellular DNA[J].Molecular Pharmacology,2000,(05):920-927.
  • 4李洁,金懋林,杨伯琴,沈琳,李燕.乐沙定联合氟脲嘧啶、甲酰四氢叶酸治疗进展期大肠癌21例分析[J].中国肿瘤临床,2001,28(4):265-266. 被引量:82
  • 5Lévi F,Misset JL,Brienza S,et a1. A chronopharmaco-logic phase II clinical trial with 5-fluorouracil,folinic acid,and oxaliplatin using an ambulatorymultichannel programmable pump high antitumor effec-tiveness against metastatic colorectal cancer[J].Cancer,1992,(04):893-900.
  • 6孙艳;周际昌.临床肿瘤内科手册[M]北京:人民卫生出版社,2003583.
  • 7Gamelin E,Gamelin L,Bossi L. Clinical aspectsand molecular basis of oxaliplatin neurotoxicity:current management and development of preventivemeasures[J].Seminars in Oncology,2002,(5 Suppl 15):21-23.
  • 8Wilson RH,Lehky T,thomas RR. Acute oxaliplat-ininduced peripheral nerve hyperexcitability[J].Journal of Clinical Oncology,2002,(07):1767-1774.
  • 9Gamelin L,Boisdron-celle M,Delva R. Preventionof oxaliplatin-related neurotoxicity by calcium andmagnesium infusions:a retrospective study of 161patients receiving oxaliplatin combined with 5-flu-orouracil and leucovorin for advanced colorectalcancer[J].Clinical Cancer Research,2004,(12Pt1):4055-4061.
  • 10郑宇,潘宏铭,楼海舟,楼芳,张在云.硫酸镁预防奥沙利铂神经毒性的临床观察[J].实用肿瘤杂志,2004,19(2):154-155. 被引量:52

二级参考文献22

  • 1金惠铭.病理生理学:第5版[M].北京:人民卫生出版社,2002.155.
  • 2Grothey A, Schmoll HJ. New chemotherapy approaches in colorectal cancer[J]. Curt Opin Oncol,2001,13(4) :275-286.
  • 3Beeouam Y, Agostini C, Trufflandier N, et al. Oradiplatin : Available data in non-colorectal gastrointestinal malignancies[J]. Crit Rev Oncol Hematol, 2001,40(3):265-272.
  • 4Cassidy J, Misaet JL. Oxalipatin-related side effects: Characteris ticsand management[J]. Semin 0neol,2002,29[5 Suppl 15] : 11-20.
  • 5Wilson RH,Lehky T,Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability[J].J Clin Oncol, 2002,20 (7):1767-1774.
  • 6Adelsherger H, Quasthoff S, Groeskreutz J, at al. The chemotherapeutic oxaliplatin alters voltage-gated Na^+ channel kinetics on rat sensory neurons[J] .Eur J Pharmacol,2000,406(1) :25-32.
  • 7Maindrault- Gocbel F, Toumigand C, Andre T, et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer[J]. Ann Oncol, 2004, 15(8) : 1210-1214.
  • 8Cersosimo RJ. Oxaliplatin-associated neuropathy: a review [J]. Ann Pharmaeother, 2005,39( 1 ) : 128-135.
  • 9Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy[J] .J Neurol,2002,249(1) :9-17.
  • 10Gamelin E, Gamelin L, Bossi L, et al, Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures [J]. Semin Oncol, 2002, 29 [ 5 Suppl 15 ] : 21-33.

共引文献135

同被引文献99

引证文献4

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部